Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (727)	11/26/1999 11:18:00 AM
From: Gary Korn	Respond to of 10345

Posts from YHOO board: Just In on CNBC by: walkersvillegetto 11/26/1999 10:02 am EST Msg: 4196 of 4196 ELN was mentioned as the top MA target in Europe next year. -------------------------- ELN on CNBC by: LA_Broker (44/M/New Orleans) 11/26/1999 9:59 am EST Msg: 4194 of 4197 Gary Kominsky, guest host on Squawk Box this a.m., just mentioned Elan as his firm's top pick going forward into 2000. --------------------- News from DLJ by: GSoros_Jr 11/26/1999 8:01 am EST Msg: 4193 of 4197 Acoording to the latest IMS data, "Elan continues to experience exceptionally strong prescription growth in its leading anti-spasticity agent, Zanaflex, as well as back pain medication, Skelaxin. Zanaflex recorded new prescription growth of 83% and total prescription growth of 73% in October. Skelaxin also showed solid relative growth with new and total prescriptions up 23% and 24%, respectively." Growth of existing products should not justifiy the heavy discount Elan is enjoying.